Search Results

You are looking at 61 - 70 of 1,305 items for :

  • Refine by Access: All x
Clear All
Full access

Luke D. Rothermel, Claire C. Conley, Anuja L. Sarode, Michael F. Young, Zulema L. Uscanga, McKenzie McIntyre, Jason B. Fleming, and Susan T. Vadaparampil

medical conditions, there is a relative dearth of research on the effects of low health literacy on postoperative outcomes. A recent systematic review of health literacy in surgery identified 51 studies addressing this topic, with only 6 that investigated

Full access

Zhi Ven Fong and Cristina R. Ferrone

. In an effort to standardize its definition, 4 organizational bodies have proposed classification systems: NCCN, the Americas Hepato-Pancreato-Biliary Association/Society of Surgical Oncology/Society for Surgery of the Alimentary Tract, The University

Full access

J. Sybil Biermann, Douglas R. Adkins, Robert S. Benjamin, Brian Brigman, Warren Chow, Ernest U. Conrad III, Deborah A. Frassica, Frank J. Frassica, Suzanne George, Kenneth R. Hande, Francis J. Hornicek, G. Douglas Letson, Joel Mayerson, Sean V. McGarry, Brian McGrath, Carol D. Morris, Richard J. O'Donnell, R. Lor Randall, Victor M. Santana, Robert L. Satcher, Herrick J. Siegel, Neeta Somaiah, and Alan W. Yasko

surgery, RT, and chemotherapy. Patients should be given a survivorship prescription to schedule follow-ups with a multidisciplinary team. Fertility issues should be discussed with appropriate patients before they start treatment. 22 Diagnostic Workup

Full access

Kathryn J. Ruddy, Lindsey Sangaralingham, Rachel A. Freedman, Sarah S. Mougalian, Heather Neuman, Caprice Greenberg, Ahmedin Jemal, Narjust Duma, Tufia C. Haddad, Valerie Lemaine, Karthik Ghosh, Tina J. Hieken, Katie Hunt, Celine Vachon, Cary P. Gross, and Nilay D. Shah

Institutional Review Board deemed this study exempt from review. Study Population We identified all women with newly diagnosed non-metastatic breast cancer treated with breast surgery (lumpectomy or unilateral mastectomy) between January 1, 2005, and May

Full access

Vishruth K. Reddy, Varsha Jain, Sriram Venigalla, William P. Levin, Robert J. Wilson II, Kristy L. Weber, Anusha Kalbasi, Ronnie A. Sebro, and Jacob E. Shabason

involving surgery, radiation oncology, medical oncology, radiology, and pathology. 2 NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for STS recommend the addition of neoadjuvant or adjuvant radiation therapy (RT) to surgery for patients

Full access

Sandra O. Gollnick

treated with PDT or surgically removed. Both before and after PDT, “we saw an increased T-cell response against that Hip1 antigen that we did not see following surgery,” Dr. Gollnick reported. This systemic antitumor immune response was inversely

Full access

Aparna Balakrishnan, Kirsten Bell Burdett, Masha Kocherginsky, and Neil Jordan

status, education status, and income. Black and AI/AN patients had higher odds of refusing recommended surgery (OR=1.95; 95% CI: 1.57-2.42; p<0.001, and OR=2.13; 95% CI: 1.11-4.10; p=0.024, respectively). Hispanic patients had slightly higher odds of

Full access

Kan Wu, Xu Liu, Zhihong Liu, Yiping Lu, Xianding Wang, and Xiang Li

Background Adrenocortical carcinoma (ACC) is a rare but highly aggressive tumor with an estimated incidence of 0.7 to 2.0 per 1,000,000 adult individuals annually. 1 Radical surgery is still the mainstay treatment of patients with

Full access

Jordan E. Rullo and Sandhya Pruthi

preoperatively. 2 For women undergoing risk-reducing surgeries for elevated breast or ovarian cancer risk or hereditary predisposition, the impact on sexual health is one of the most influential factors when deciding to undergo these surgeries. 3 Among BRCA

Full access

Andrea Cercek, Karyn A. Goodman, Carla Hajj, Emily Weisberger, Neil H. Segal, Diane L. Reidy-Lagunes, Zsofia K. Stadler, Abraham J. Wu, Martin R. Weiser, Philip B. Paty, Jose G. Guillem, Garrett M. Nash, Larissa K. Temple, Julio Garcia-Aguilar, and Leonard B. Saltz

those of local recurrence. 1 , 2 The current standard management for stage II (T3/T4N0) and stage III (TanyN1/N2) rectal cancer is neoadjuvant chemoradiotherapy, followed by surgery, with 4 months of adjuvant systemic chemotherapy given at the end. 1